Healio Special Report: Health Care and Politics

Healio Special Report: Health Care and Politics

September 05, 2017
3 min read

Trump budget cuts threaten antimicrobial stewardship

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Helen Boucher, MD
Helen W. Boucher

The significant budget cuts proposed by President Donald J. Trump’s administration threaten recent progress on combating antimicrobial resistance, according to a commentary published in Annals of Internal Medicine.

“By 2050, a total of 350 million cumulative deaths will likely be attributable to [antimicrobial resistance] if current trends continue,” Helen W. Boucher, MD, director of the infectious diseases fellowship program at Tufts Medical Center and associate professor of medicine at Tufts University School of Medicine, and colleagues wrote. “In the past 2 years, national and global leaders have united against this threat, making tangible progress. However, budget cuts of a historic magnitude proposed by the Trump administration now threaten to undo this progress, placing patients in grave danger.”

The 21st Century Cures Act, enacted in 2016, allows for patients with serious or life-threatening infections who are taking antibacterial and antifungal drugs to be studied in smaller, faster clinical trials. With $379 million in funding from Congress, health experts and leaders across the U.S. have worked to fight antimicrobial resistance over the past 2 years, according to Boucher and colleagues. This funding has been used to improve investment in rapid detection and response to outbreaks and emerging resistance, expand tuberculosis screenings, enhance prevention networks in health care settings and promote appropriate antibiotic stewardship, they wrote; however, because the Trump administration seeks significant cuts to funding for public health and research, these efforts are at risk of being undone.

In May 2017, the president released a budget request that proposes to cut the National Institute of Allergy and Infectious Disease’s funding by 23% and the CDC's antimicrobial resistance funding by 14%, positioning it within the Prevention and Public Health Fund, which the administration and Congress are seeking to repeal, Boucher and colleagues wrote. The budget would also cut the United States Agency for International Development's global health programs by 51% and its tuberculosis program by 26%. The proposed cuts would significantly lessen the ability to monitor antimicrobial resistance; prevent infection and promote stewardship; and support the development of new antimicrobial drugs, diagnostics and vaccines. The cuts would also hinder the global health security efforts of the CDC and United States Agency for International Development by substantially reducing support for global surveillance and increasing the chance that multidrug-resistant pathogens will spreading across borders undetected, according to Boucher and colleagues.

“Over the past 2 years, our nation’s health experts and leaders have worked diligently to enable the United States to tackle [antimicrobial resistance] head-on. If now enacted, these proposed budget cuts would reverse this course, which would go against the widespread agreement of experts and be to the detriment of our nation,” Boucher and colleagues wrote. “Given the severity of the threat posed by [antimicrobial resistance], and the United States' position as a world leader traditionally at the forefront of global progress, we believe that we must reaffirm our investment in research and public health efforts to combat this threat.” – by Savannah Demko

Disclosures: Boucher reports personal fees from Infectious Diseases Society of America and from NIH’s Antibacterial Resistance Leadership Group. Please see the full article for a complete list of all other authors’ relevant financial disclosures.